tirzepatide being discontinued Adults with obesity who discontinue semaglutide, achieve minimal weight loss The Impact of New FDA

slower dose titration and dietary modifications can reduce severity and duration

This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue

While safety research around semaglutide continues to evolve, regulators have also scrutinized how these drugs are marketed

These establish a reference point for monitoring efficacy and tolerability as doses escalate

That is because the patent on semaglutide the drug that mimics the naturally-produced hormone glucagon-like peptide-1 (GLP-1) that regulates blood sugar, appetite and digestion expires in China next year

3